Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
Portfolio Pulse from Avi Kapoor
AngioDynamics, Inc. (NASDAQ:ANGO) is set to release its Q1 earnings on Oct. 3, with analysts expecting a loss of 15 cents per share and revenue of $67.93 million. The company recently received CE Mark approval for its Auryon System in Europe. Analysts have mixed ratings, with price targets ranging from $10 to $14.
October 03, 2024 | 7:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AngioDynamics is expected to report a Q1 loss of 15 cents per share, with revenue of $67.93 million. The company received CE Mark approval for its Auryon System in Europe, which could positively impact future revenues. Analysts have mixed ratings, with price targets between $10 and $14.
The upcoming earnings report is crucial for AngioDynamics, with expectations of a loss indicating potential short-term pressure on the stock. However, the recent CE Mark approval for the Auryon System in Europe is a positive development that could enhance future revenue streams. Analyst ratings are mixed, suggesting uncertainty in the stock's short-term direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100